In patients with the irritable bowel syndrome (IBS), are smooth-muscle relaxants safe and efficacious for global improvement of symptoms?
D a t a e x t r a c t i o n
Data were extracted on study quality, patient characteristics and numbers, drug and dosage, treatment duration, and outcomes.
M a i n r e s u l t s 23 trials (1888 patients) met the inclusion criteria. 6 drugs were studied: cimetropium bromide (5 trials), hyoscine butyl bromide (3 trials), mebeverine (5 trials), otilium bromide (4 trials), pinaverium bromide (2 trials), and trimebutine (4 trials). All drugs analyzed together and each drug analyzed separately, except pinaverium alone, showed improvement in global symptom ratings (Table) . All drugs combined (and otilium and cimetropium alone) reduced pain (Table) . Abdominal distention was improved with all drugs (Table) , but constipation or transit was not. The percentage of patients with adverse effects did not differ for all drugs compared with placebo or for individual drugs.
C o n c l u s i o n
Smooth-muscle relaxants improve the global rating of symptoms and reduce pain in patients with the irritable bowel syndrome. C o m m e n t a r y IBS represents a heterogeneous group of disorders presenting with similar clinical symptoms. Altered motility is thought to be important in a subset of patients with IBS, and this concept forms the foundation for the use of smooth-muscle relaxants. 3 recent meta-analyses, including the review by Poynard and colleagues, have evaluated smooth-muscle relaxants for IBS (1, 2) . Each found such agents better than placebo for global improvement and abdominal pain. The latest, the review by Poynard and colleagues, differs from its predecessors by excluding peppermint oil and dyciclomide bromide and including 6 additional randomized, non− English-language trials. Although smooth-muscle relaxants appear superior to placebo, Poynard and colleagues suggest that only approximately 50% of treated patients will experience global improvement and only 40% will have an improvement in abdominal pain. In addition, the results do not indicate which individuals are most likely to improve with these agents. Perhaps most important, only 1 of the drugs included in this meta-analysis, hyoscine, is available in the United States, and it showed the least benefit for global improvement or abdominal pain over placebo.
If one accepts the issues noted above, it seems reasonable to conclude that as a class, smooth-muscle relaxants can benefit a subset of patients with IBS. Unfortunately, whether the results are generalizable to agents available to physicians in the United States remains an open question.
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